VP-16

ApprovedSmall molecule

FFundamenta Therapeutics, Ltd.

VP-16 is one of 206 small molecule programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

RetinoblastomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Ovarian CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

RetinoblastomaPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 3

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

VP-16

FFundamenta Therapeutics, Ltd.

Approved

2 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT02036489·107 enrolled

Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

Unknown status·PPETHEMA Foundation·Phase 2·NCT02776605·30 enrolled

Lymphoma2 trials

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Completed·—·N/A·NCT01702961·75 enrolled

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01538472·40 enrolled

Treatment1 trial

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Conditioning1 trial

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT01873807·100 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005797·125 enrolled

9 more indications

Prophylaxis1 trial

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Completed·SStanford University·Phase 2·NCT00350181·11 enrolled

Ovarian Cancer1 trial

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Unknown status·ZZhongda Hospital·Phase 2·NCT05422183·20 enrolled

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Unknown status·FFundamenta Therapeutics, Ltd.·Phase 1·NCT05576181·19 enrolled

Lymphoid Malignancies1 trial

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT00250718·17 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

Retinoblastoma1 trial

Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

Completed·—·Phase 2·NCT00179920·30 enrolled

B-cell Malignancies1 trial

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Unknown status·ZZhejiang University·Phase 1·NCT05379647·24 enrolled

Cell Therapy1 trial

Natural Killer(NK) Cell Therapy in r/r AML

Unknown status·ZZhejiang University·Phase 1·NCT05665114·18 enrolled

Acute Myeloid Leukemia1 trial

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Unknown status·ZZhejiang University·Phase 1·NCT05665075·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for VP-16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VP-16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VP-16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundamenta Therapeutics, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFundamenta Therapeutics, Ltd.

VP-16

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Lymphoma2 trials

Treatment1 trial

Conditioning1 trial

Bone Marrow Transplant1 trial

Prophylaxis1 trial

Ovarian Cancer1 trial

B-cell acute lymphoblastic leukemia1 trial

Lymphoid Malignancies1 trial

Diffuse Large B-Cell Lymphoma1 trial

Retinoblastoma1 trial

B-cell Malignancies1 trial

Cell Therapy1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News